PTEN has been associated with a favorable outcome in endometrial cancer, and pre-clinical data have shown that inactivating mutations in the PTEN gene may confer sensitivity to PI3K-AKT inhibitors as well as PI3K/mTOR inhibitors (14, 45). This evidence concerns the gene MTOR and endometrial cancer.